The US company claims to be redefining neuroscience research and development with a data-driven precision neuroscience platform to cut through brain disease heterogeneity to match the right patient populations to targeted therapeutics.

Neumora was founded in 2021 as a response to the lack of targeted, effective medicines for brain diseases and the high failure rate that has plagued neuroscience drug development for decades.

The firm has raised more than $500 million, including a $100 million equity investment from US biotech Amgen.